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Objective The generation of acinar and ductal cells
from human pluripotent stem cells (PSCs) is a poorly
studied process, although various diseases arise from
this compartment.
Design We designed a straightforward approach to
direct human PSCs towards pancreatic organoids
resembling acinar and ductal progeny.
Results Extensive phenotyping of the organoids not
only shows the appropriate marker proﬁle but also
ultrastructural, global gene expression and functional
hallmarks of the human pancreas in the dish. Upon
orthotopic transplantation into immunodeﬁcient mice,
these organoids form normal pancreatic ducts and acinar
tissue resembling fetal human pancreas without evidence
of tumour formation or transformation. Finally, we
implemented this unique phenotyping tool as a model to
study the pancreatic facets of cystic ﬁbrosis (CF). For the
ﬁrst time, we provide evidence that in vitro, but also in
our xenograft transplantation assay, pancreatic
commitment occurs generally unhindered in CF.
Importantly, cystic ﬁbrosis transmembrane conductance
regulator (CFTR) activation in mutated pancreatic
organoids not only mirrors the CF phenotype in
functional assays but also at a global expression level.
We also conducted a scalable proof-of-concept screen in
CF pancreatic organoids using a set of CFTR correctors
and activators, and established an mRNA-mediated gene
therapy approach in CF organoids.
Conclusions Taken together, our platform provides
novel opportunities to model pancreatic disease and
development, screen for disease-rescuing agents and to
test therapeutic procedures.
INTRODUCTION
Given their capacity to differentiate into every cell
type of the human body, human-induced pluripo-
tent stem cells (hiPSCs) provide a unique platform
for developmental studies and regenerative medi-
cine.1–4 The generation of pancreatic progenitor
Signiﬁcance of this study
What is already known on this subject?
▸ Human pluripotent stem cells (PSCs) present a
powerful tool for developmental studies and
regenerative medicine.
▸ Directed differentiation of PSCs towards
pancreatic cell fates requires the formation of
PDX1/NKX6.1-positive progenitor cells.
▸ Mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR) perturb ﬂuid
transport causing chronic airway infections or
biliary cirrhosis with variable phenotypes while
the pancreas is one of the ﬁrst organs affected.
What are the new ﬁndings?
▸ Efﬁcient generation of high yields of pancreatic
progenitors from several human pluripotent
stem cell lines.
▸ PSC-derived pancreatic progenitors form
pancreatic organoids that comprise acinar/
ductal-like progeny and resemble human
pancreas upon orthotopic transplantation in
mice.
▸ Induced PSCs from cystic ﬁbrosis patients
display normal pancreatic commitment in vitro
and in vivo at least until a fetal developmental
stage.
▸ Pancreatic organoids from patients with cystic
ﬁbrosis recapitulate defective CFTR function in
vitro, allowing subsequent drug screening but
also mRNA-mediated gene supplementation.
How might it impact on clinical practice in
the foreseeable future?
▸ Our system provides a novel approach to model
human pancreatic development and disease.
▸ Humanised platform for (organ-speciﬁc and
patient-speciﬁc) drug screening and testing of
therapeutic options in vitro and in vivo.
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(PP) cells from PSCs follows the sequential induction of virtu-
ally pure deﬁnitive endoderm (DE), foregut endoderm (GTE)
and pancreatic endoderm (PE, ﬁgure 1A).5–7 Over the last
decade, a series of studies have aimed at improving pancreatic
differentiation protocols.5–7 While most studies focused on the
generation of PDX1-positive PE,8 9 true PP cells should coex-
press both NKX6.1 and PDX1.10 While the exocrine and endo-
crine lineages develop, NKX6.1 is still expressed in β cells, but
becomes mutually exclusive with the expression of Ptf1a driving
the exocrine lineage.11 Thus, the presence of NKX6.1 is one of
the key distinguishing features of these two lineages and hence
can be used to monitor the emergence of true progenitors.
Despite recent progress in differentiating PSCs towards endo-
crine pancreatic progeny,12 13 the generation of ductal and
exocrine-like cells has not yet been adequately achieved, apart
from a recent study modelling human pancreatic cancer.14
Three-dimensional organoid models generated from PSCs can
faithfully model the in vivo situation,13 15 16 and disease-speciﬁc
iPSCs allow the generation of distinct human disease
models.12 13 15 Nevertheless, the generation of human pancreas
in mice upon xenotransplantation of non-transformed organoids
has not been achieved to date. However, this would open up
entirely new research avenues. In addition, inherited pancreatic
diseases would beneﬁt from in vivo gene supplementation strat-
egies as recently shown for a lung disease with speciﬁcally modi-
ﬁed mRNA, pre-evaluated in organoids.17 18 To tackle this
unmet need in the pancreatic ﬁeld, we describe herein a new
PSC-based organoid system that was used to model pancreatic
aspects of cystic ﬁbrosis (CF).
CF is an inherited disease caused by either nonsense or mis-
sense mutations in the cystic ﬁbrosis transmembrane conduct-
ance regulator (CFTR) gene, resulting in complete absence of
the protein, a misfolded polypeptide that is degraded by the
unfolded protein response, or a dysfunctional protein.19 CFTR
encodes a chloride channel gated by cyclic AMP-dependent
phosphorylation that is necessary for electrolyte and ﬂuid
homeostasis of epithelia in various organs including the lung,
liver, intestine and pancreas. Dysfunction of the CFTR leads to
the production of hyperviscous mucus causing chronic airway
infections or biliary cirrhosis with variable phenotypes.20
Although the pancreas is one of the ﬁrst organs affected, knowl-
edge about the pathophysiology of the pancreas during CF is
limited. Brieﬂy, distinct CFTR genotypes have been shown to
not only increase the probability of developing either pancrea-
titis or perinatal exocrine insufﬁciency21 but also pancreatic
cancer.22 Moreover, exocrine insufﬁciency drives a complex and
poorly understood cascade of events leading to endocrine
exhaustion.23 Additionally, the expression of the CFTR gene
during early pancreatic development suggests that CFTR muta-
tions could have a developmental impact;24 however, current
CF animal models recapitulate only limited aspects of the
human disease sparing the pancreas, and in vitro studies have
been hampered by the lack of primary human pancreatic
progeny. Moreover, with increasing CF patient survival pancre-
atic manifestations of CF are becoming progressively more clin-
ically relevant but the underlying pathomechanisms remain to
be explored. Thus, innovative model systems for pancreatic CF
and other pancreatic disorders are clearly warranted.
MATERIALS AND METHODS
Differentiation of human PSCs into PP cells
For differentiation, human PSCs were grown to 95% conﬂuence
on growth factor-reduced matrigel (BD, 354 230) and FTDA
medium25 was refreshed 3 hours before initiating
differentiation. The backbone medium for the ﬁrst 6 days of dif-
ferentiation was BE1: MCDB131 (Invitrogen) with 0.8 g/L cell
culture tested glucose (Sigma), 1.174 g/L sodium bicarbonate
(Sigma), 0.1% fatty acid free (FAF) BSA (A7030, Sigma), 2 mM
L-glutamine. Later differentiation was performed in BE3 as the
backbone medium: MCDB131 with 0.44 g/L glucose, 1.754 g/L
sodium bicarbonate, 2% FAF-BSA, 2 mM L-glutamine, 44 mg/L
L-ascorbic acid, 0.5× insulin-transferrin-selenium-ethanolamine
(ITS-X). Cells in differentiation were cultured at 37°C in a 5%
CO2 incubator with daily media change. For the ﬁrst day of dif-
ferentiation, cells were washed with phosphate buffered saline
(PBS) (Sigma) and incubated with BE1 supplemented with
3 mM GSK3β-inhibitor (CHIR99021) (Axon MedChem) and
100 ng/mL Activin A. The next day the medium was replaced
by BE1 with 100 ng/mL Activin A. After 3 days, media was
changed to BE1 with 50 ng/mL KFG (Peprotech) for 2 days.
From day 6 until day 10, cells were cultured in BE3 medium
containing 0.25 mM SANT-1 (Sigma), 2 mM retinoic acid
(Sigma), 200 nM LDN-193189 (Sigma) and 500 nM
PD0325901 (Calbiochem). At days 10–14, the cells received
BE3 supplemented with 50 ng/mL ﬁbroblast growth factor
(FGF10) (Peprotech), 330 nM Indolactam V (Stem Cell
Technologies), 10 mM SB431542 (Axon MedChem) and add-
itional 16 mM glucose. An outline of the differentiation proto-
col can also be found in ﬁgure 1A.
3D pancreatic organoid culture
At the PP stage (day 12 of differentiation), cells were washed
with PBS, incubated with TrypLE at 37°C for 5–6 min and care-
fully resuspended in DMEM/F12 resulting in clumps of 3–10
cells. After centrifugation at 400 g for 5 min, the pellet was
washed in BE3 medium, centrifuged again and resuspended in
precooled day 12 medium (detailed above) supplemented with
10 mM Rock inhibitor. The cell suspension was mixed on ice
with growth factor reduced matrigel at a 1:3 ratio and 25 mL
were transferred to a 48-well plate (NunclonΔSurface).
Following incubation for 10 min at 37°C, the solidiﬁed drop of
matrigel was overlayed with 200 mL of day 12 medium (see
above) containing 10 mM Rock inhibitor (always added for the
ﬁrst 4 days in three-dimensional (3D) culture), which was
replaced the next day. On day 14, differentiation was continued
with 10 ng/mL FGF2 and 10 mM Rock inhibitor in BE3
medium. From day 18 on, organoids were cultured in BE3 with
10 ng/mL FGF2 and 10 mM nicotinamide (NA) (Sigma)
(referred to as ‘FN’). Medium was changed every 2–3 days.
Alternatively, organoids were generated by replating PPs in sus-
pension in ultra-low-attachment plates (Corning). To prevent
aggregation, cell clusters were triturated after 1 hour and again
after 2 days. For changing media, half of the ﬂuid was pipetted
off and replaced with fresh differentiation media. Medium con-
ditions were identical to the matrigel-based culture. For suspen-
sion cultures, another medium (referred to as ‘FEPC’) was
tested (based on conditions published for mouse embryonic
PPs26) composed of DMEM/F12, 10% knockout serum replace-
ment (KOSR) and 0.1 mM β-mercaptoethanol supplemented with
50 ng/mL FGF10, 25 ng/mL epidermal growth factor (EGF)
(novoprotein), 2 mM CHIR99021 and 16 nM phorbol myristate
acetate (Sigma). For passaging, matrigel was scraped off, pipetted
in order to mechanically dissociate the organoids into small
clumps, collected in a 15 mL falcon, and further processed as
described above. Organoids were passaged every 10–14 days and
cultured at 5% CO2 and 37°C.
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Functional CFTR assay
Organoids were split 1:4 and 8 mL of the cell/matrigel suspen-
sion was transferred to the inner border of each well of a
96-well plate (NunclonΔSurface), solidiﬁed for 5 min and
100 mL culture medium was added. Six days after seeding, orga-
noids were incubated with 20 mM forskolin (FSK) and 100 mM
3-isobutyl-1-methylxanthine (IBMX) (or 1:500 dimethyl sulfox-
ide (DMSO) (all from Sigma) as negative control) in FN
Figure 1 Pancreatic progenitor cells derived from human pluripotent stem cells (PSCs). (A) Schematic outline of the developed protocol. Growth
factors, small molecules and timing are indicated. DE, deﬁnitive endoderm; GTE, gut-tube endoderm; PE, pancreatic endoderm; PP, pancreatic
progenitor. (B) Overview of ﬂuorescence-activated cell sorting (FACS) results during protocol optimisation to generate true PPs. A, Activin A; K,
keratinocyte growth factor (KGF); L, LDN-193189; PD, PD0325901; R, retinoid acid; S, SANT-1 . (C) qPCR at the PP stage comparing a previously
described protocol53 with our optimised protocol (ﬁrst vs last row in B, fold change, PP markers as indicated). Data are presented as mean±SEM,
n=3 experiments, statistical signiﬁcance was determined by two-tailed t-test, *p<0.05, ***p<0.001. (D and E) Immunostaining (left) and
representative FACS plots (right) for the indicated markers ((D) day 10; (E) day 14). (F) FACS-based quantiﬁcation of PDX1/NKX6.1-double positive
cells generated after 13 days of PP differentiation from HUES8 cells using the ‘Kieffer’13 protocol or our ‘own’ protocol (see A) in seven different PSC
lines (indicated by different colours). Dots represent independent experiments. Boxes show the median, and the 25th and 75th percentiles. The
whiskers of the graph show the largest and smallest values. (G) Amylase-positive cells derived after 24 days of pancreatic differentiation in
monolayer culture. If not stated otherwise, all data were obtained using HUES8 cells. Scale bars: 100 mm.
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medium for 2 hours at 37°C. The forskolin-induced swelling
assay was performed as described before in ref 27. Pictures were
captured before and immediately after treatment using a
Keyence Biozero BZ-9000 microscope. Images were manually
analysed and spheres were also encircled manually. To quantify
the surface area increase relative to the organoid area before
CFTR induction (0 hour), we used the area measurement appli-
cation of the BZII-analyser software (Keyence). The mean area
increase (of at least 30 organoids) was calculated per well fol-
lowed by summarising the results of three individual wells per
condition.
CFTR corrector screen
For screening CFTR modulators, organoids (cultivated in matri-
gel for 6 days) were preincubated with the respective com-
pound, or combinations thereof, diluted to 10 mM (DMSO,
1:500 was used as control) in FN medium for 24 hours (except
for P4 and P9, which were applied during forskolin (FSK) treat-
ment only), and the functional CFTR assay was subsequently
carried out as described above. The effect of selected hit com-
pounds was quantiﬁed by measuring the mean area increase
after CFTR induction in all organoids (8–12 organoids per con-
dition) using ImageJ. All CFTR corrector and potentiator com-
pounds, speciﬁed in online supplementary table S1, were
provided by the Cystic Fibrosis Foundation Therapeutics.
RESULTS
Genuine PP cells from human PSCs
Recent studies have described a complex sequential arrangement
of growth factors to generate high numbers of PPs.12 13
Therefore, we implemented, ﬁne-tuned and speciﬁcally tailored
a previously described protocol for our requirements: (i) by
limited use of growth factors in exchange with cost-effective
small molecules instead, (ii) a PP suitable for acinar/ductal
lineage commitment and (iii) broad applicability across various
human PSC lines has been generated (ﬁgure 1A). The growth
factors and small molecules used included the sonic hedgehog
antagonist SANT1,28 LDN193189 as an inhibitor of bone mor-
phogenetic protein (BMP) signalling, the mitogen-activated
protein kinase (MEK) inhibitor PD0325901, FGF2 and
FGF10,29 SB431542 to inhibit transforming growth factor-β
(TGF-β)-signalling,30 NA and Indolactam V to promote PP
expansion and exocrine speciﬁcation.31 32 Details of our pilot
tests are outlined in the online supplementary results in supple-
mentary ﬁgures S1–3 and ﬁgure 1B, C. Brieﬂy, high yields of
PDX1-positive PE were achieved by retinoic acid treatment,
sonic hedgehog (SHH) and BMP inhibition, and inhibition of
MEK/ERK-signalling (ﬁgure 1D). Similarly, we optimised the
commitment towards PDX1/NKX6.1-positive PPs (ﬁgure 1B, C,
E, F and online supplementary ﬁgures S2 and S3) with a
combination of Indolactam V,31 FGF10 and SB431542 in high-
glucose, serum-free media. This protocol robustly allowed the
generation of up to 70% PDX1/NKX6.1-positive PPs across
several human PSC lines (ﬁgures 1E, F, 4C, F and online supple-
mentary ﬁgure S8). This combination also resulted in the stron-
gest increase in PP-marker gene expression (ﬁgure 1C) while
non-pancreatic lineage marker gene expression was lowest
under these conditions (see online supplementary ﬁgure S3C).
Cell death was virtually absent at various intermediate stages,
while PPs remained proliferative (see online supplementary
ﬁgure S4). To provide an objective rating of the quality of our
protocol, we applied a protocol published in a recent landmark
study,13 which aimed to develop β cells from PDX1/
NKX6.1-positive PPs, to HUES8 cells and found similar, if not
superior, results with our protocol across seven different human
PSC lines (ﬁgure 1F). Upon subsequent monolayer differenti-
ation (using FGF2 and then FGF2+NA) to test our novel PP
population for its exocrine differentiation capacity, we observed
the generation of some amylase (AMY)-positive cell clusters
(ﬁgure 1G).
Pancreatic organoids efﬁciently generate acinar-like and
ductal-like progeny
It has been shown that human PSC-derived organoids emphasise
maturation and functionality across several cell types.33 34 In
order to direct lineage differentiation of PPs in favour of pancre-
atic maturation, 3D culture conditions were employed (ﬁgure
1A, right). Whether reseeded into suspension or embedded into
matrigel, PPs rapidly formed cyst-like structures further referred
to as pancreatic organoids (POs) (ﬁgure 2A and online supple-
mentary ﬁgures S5A and S9A). Of note, organoids arose from
cell clusters comprising on average 4–5 cells (ﬁgure 5A and
online supplementary ﬁgure S5A). Intriguingly, POs could be
expanded for >6 passages and regrew upon subsequent
freeze-thaw cycles (not shown). Maturated organoids expressed
pancreatic exocrine markers such as AMY or chymotrypsin C
(CTRC), ductal markers such as SOX9 and cytokeratin 19
(CK19) and also CFTR, as well as the epithelial marker
E-cadherin and the progenitor marker NKX6.1 (ﬁgure 2B–G).
While we observed heterogeneity in pancreatic maturation across
all organoids, POs with a relevant architecture of acinar/ductal
progeny contained 34%±15% acinar and 61%±19% ductal
cells. Interestingly, organoids arising from reaggregated,
FACS-puriﬁed PPs derived from an NKX6.1-GFP reporter
embryonic stem cell (ESC) line displayed similar morphology,
further substantiating the pronounced pancreatic fate of the orga-
noids (see online supplementary ﬁgure S5B–E). In particular, POs
exhibiting a hollow central lumen displayed a basal lamina and
signs of apical-basal polarity as shown by staining for the apical
marker ZO1 and basal marker laminin-α5 (ﬁgure 2H). We could
not detect relevant amounts of apoptosis (cleaved CASP3) and
each organoid contained a few Ki67-positive cells indicating prolif-
eration (ﬁgure 2I). Ultrastructural analysis revealed typical ductal
morphology with microvilli (arrow) and tight junctions (double
arrowhead) but also acinar-like cells as identiﬁed by secretory
granula (arrowhead) and lumen formation (asterisk, ﬁgure 2J).
POs are functional and globally cluster with human
pancreas
To functionally assess our PO cultures, we applied an enzymatic
assay to measure carbonic anhydrase (CA) activity in duct-like
cells. CA is a key enzyme expressed in pancreatic ducts to cata-
lyse the reaction CO2+H2O=HCO3
−+H+. Indeed, organoids
showed CA activity in a similar range as freshly isolated primary
ductal cells (ﬁgure 2K). Additionally, enzymatic activity for key
acinar enzymes such as AMY, trypsin and elastase could be
detected (ﬁgure 2L). Similar to the aforementioned heteroge-
neous pancreatic marker expression proﬁle, enzymatic activity
also varied across individual organoids.
Next, we performed global gene expression analysis of
PSC-derived POs and applied unsupervised clustering analysis in
an attempt to globally assess the maturation stage of our cul-
tures. Accordingly, transcriptome comparison with reference
data sets from the literature35–37 revealed clustering of POs close
to human adult pancreatic tissue but also with acinar and ductal
cells derived from human pancreas. In contrast, POs clustered
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away from somatic cells such as keratinocytes and ﬁbroblasts and
human PSC (ﬁgure 2M). In addition, pancreas-speciﬁc gene sig-
natures conﬁrmed such clustering (see online supplementary
ﬁgure S6 and table S4). Thus, POs faithfully recapitulate human
pancreatic tissue based on protein markers, gene expression pro-
ﬁling and function. Taken together, these results would suggest
that our system of POs is suitable for drawing conclusions on
human disease.
Plucked human hair to generate CF-speciﬁc induced PSCs
Next, we aimed to generate a disease model for CF as an appli-
cation for this PO model system. Clonal iPSC lines from two
patients with CF and healthy donors were generated via
reprogramming of keratinocytes derived from plucked human
hair (ﬁgure 3A).38 39 Expanded clones displayed hallmarks of
pluripotency as judged by immunostaining and mRNA expres-
sion of pluripotency markers such as OCT3/4, NANOG, SSEA4
and SOX2 (ﬁgure 3B–D). Gene expression proﬁling also
showed clustering of CF lines close to HUES8 human embry-
onic stem cells but also together with iPSC samples from public
databases. Of note, all pluripotent cell lines were located apart
from somatic counterparts (ﬁgure 3E). Next, we conﬁrmed the
genotype of the two patients with CF by targeted sequencing of
the CFTR gene in cultured iPSCs (ﬁgure 3F, G). Cells were
derived from two unrelated individuals affected by (classical)
CF. The ﬁrst patient (CF-P1, ﬁgure 3F) was homozygous for
Figure 2 Pancreatic organoids containing acinar-like /duct-like cells. (A) Brightﬁeld view of pancreatic organoids (POs) in FN (left) or FEPC (right)
medium (for details, see online supplementary ﬁgure S9). Scale bars: 50 mm. (B–G) Immunostaining of POs for the indicated markers. CTRC,
chymotrypsin C; ECADH, E-cadherin. (E) Acinar-like cells staining positive for amylase (AMY) are mostly excluded from NKX6.1-positive regions
(marked by arrowhead). (F) SOX9-positive cells mainly do not express NKX6.1 (indicated by arrowhead). (H) Analysis of polarity in organoids derived
in matrigel-based culture conditions showing basolateral expression of laminin-α5 (LAM) and apical localisation of the tight junction protein ZO1. (I)
Staining for Ki67 and cleaved caspase 3 (CASP3) indicating proliferation and very few apoptotic cells (marked by asterisk) in organoids derived in
matrigel. Scale bars: (B, H, I) 20 mm, (C–G) 25 mm. ( J) Electron microscopy of POs harbouring duct-like and acinar-like structures. Marked inlets are
depicted in the lower row and show microvilli (arrows), tight junctions (double arrowheads) and secretory granules (arrowheads); asterisks mark the
lumen. Scale bars: 5 mm (upper row), 2 mm (upper row middle) or 1 mm (bottom row). (K) Carbonic anhydrase (CA) assay reﬂecting enzymatic
activity of POs compared with primary pancreatic ductal cells (PDC) depicted as ng CA/10 mg protein (means of two triplicate measurements±SEM
are shown). (L) Digestive enzyme activity in POs generated in suspension culture (FN medium). Trypsin and elastase activity is given as RFU/min/mg
protein and amylase activity is indicated in mU calculated against puriﬁed enzyme (porcine amylase). Measurements were performed in triplicates
and results are represented as mean±SD. (M) Hierarchical clustering shows in-house generated data (ie, HUES8, Con-iPSCs and CF-P1/P2-derived
POs) clustered with acinar, small/large ductal cells (E-MTAB-463) and adult human pancreas (GSE72492) and are clearly separated from pluripotent
stem cells (PSCs) (GSE56130, GSE63101) and other somatic cells (ie, human keratinocytes, GSE63101; human foreskin/lung ﬁbroblasts (HFF/HLF),
GSE55820). If not indicated otherwise, all data were obtained in human ES cell (HUES8)-derived POs.
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the mutation c.3276C>A (p.Y1092*), and the second patient
(CF-P2, ﬁgure 3G) was compound heterozygous for the muta-
tions c.1521_1523delCTT (p.F508del) and c.3773dupT
(p.L1258Ffs*7). All three mutations are well-known mutations
and lead to a complete or near-complete loss of function of the
CFTR protein (class I or II). Further details are provided in the
online supplementary materials and methods section.
PSCs from patients with CF display normal commitment
towards PPs
To demonstrate the eligibility of our organoid system to model
pancreatic development and human disease, we focused on the
pancreatic aspects of CF. It is assumed that mucus accumulating
within the ductal lumen of tubular structures leads to ob-
struction and subsequent acinar degeneration. Although this
sequence of events appears logical, it remains unclear whether
mutated CFTR alters human pancreatic development, as sug-
gested by its early expression and the pronounced perinatal
damage in case of severe mutations.21 As such, we ﬁrst assessed
DE formation via surface marker cell cytometry for CXCR4
and c-KIT and immunostaining for SOX17 and FOXA2.
Interestingly, commitment towards DE occurred in CF-iPSC
lines at the same purity as in control lines (ﬁgure 4A, D and
online supplementary ﬁgure S7). Similarly, formation of
PDX1-positive PE was uniform across all genotypes and sub-
clones upon directed pancreatic differentiation (ﬁgure 4B, E and
online supplementary ﬁgure S8A). Applying our novel protocol
to generate NKX6.1/PDX1-double positive PPs (ﬁgure 1A) also
revealed no genotype-linked differences (ﬁgure 4C, F and
online supplementary ﬁgure S8B, C).
POs display a CF phenotype
We hypothesised that in POs a CF phenotype might become more
traceable compared with the in vivo situation. Intriguingly,
CF-POs developed without gross abnormalities in size and morph-
ology, suggesting that this commitment step towards acinar-like/
duct-like cells is unaltered in CF (ﬁgure 5A and online supplemen-
tary ﬁgure S9A). Also, we did not observe obvious changes in
polarity, proliferation and apoptosis but also lineage fate within
wild-type (WT) and CF POs as assessed via qPCR and immunos-
taining (see online supplementary ﬁgure 9B–D). Forskolin and
IBMX activate CFTR and lead to subsequent ﬂuid secretion into
the organoid lumen;27 however, this effect should be disturbed in
CF POs. Indeed, while in WTorganoids swelling was pronounced,
CF organoids remained unchanged (ﬁgure 5B, C). To further test
CFTR function in both patient and control organoids, we
used MQAE (N-(ethoxycarbonylmethyl)-6-methoxyquinolinium
bromide), a ﬂuorescent dye quenched by the presence of chloride
but not affected by other anions or pH changes, to visualise func-
tional alterations in the respective organoid genotypes.
Interestingly, the expected differences in chloride content within
the organoid lumen could be observed (ﬁgure 5D).
Next, we searched for transcriptional evidence of a CF pheno-
type in patient-derived organoids. Previous transcriptome studies
from F508del mutated native nasal epithelial cells identiﬁed char-
acteristic gene signatures in human CF airway.35 We applied the
latter gene sets for gene set enrichment analysis to the transcrip-
tomes of CF and control PO samples. Indeed, we noted similar
enrichment patterns in our PO samples for cell proliferation and
defence response as well as for ESR1-target genes (ﬁgure 5E).
Thus, molecular signatures established in CF nasal epithelium
could be reidentiﬁed in POs with mutant CFTR, indicating
common disease mechanisms across the affected organs in CF.
A compound screen in POs to rescue the CF phenotype
The pronounced swelling difference upon CFTR activation
between control and CForganoids makes our platform an interest-
ing model to identify novel drugs ameliorating pancreatic CFTR
Figure 2 Continued.
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Figure 3 Modelling pancreatic cystic ﬁbrosis (CF) with disease-speciﬁc human-induced pluripotent stem cells (iPSCs). (A) Reprogramming outline
of plucked human hair (with outer root sheath (ORS)) keratinocytes (ker) from a patient with CF towards iPSCs. (B–D) Representative
immunostaining (B, C) and qPCR analysis (D) for indicated pluripotency markers in a control-iPSC line and two CF-iPSC lines derived from
independent CF individuals. Scale bars: 50 mm. Error bars represent mean±SEM, n=3. (E) Hierarchical clustering shows a high similarity between
CF-iPSCs and pluripotent cells, including human embryonic stem cells (HUES8, own cultures; H1, GSM1040172; H9, GSM1040173) and human iPSCs
established elsewhere (hiPSC_1, GSM1040179; hiPSC_2, GSM1040180). All pluripotent cell types are labelled in blue. CF-iPSCs show a high
dissimilarity with and clustered away from somatic cell types such as peripheral blood monocytes (PBMN_1, GSM1040233; PBMN_2, GSM1040234),
cord blood cells CB_1, GSM104023; CB_2, GSM1040232) and human dermal ﬁbroblasts (HDF, GSM1040229). All somatic cell types are labelled in
red. (F and G) DNA chromatogram of patient CF-P1 (F) and of patient CF-P2 (G) depicting the mutated nucleotides (arrows) in the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) gene locus. Note the two different mutations at different positions of the CFTR gene in CF-P2.
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function. Accordingly, we compiled a set of small-molecule com-
pounds that should improve cellular processing (termed CFTR
correctors) and/or gating function of the CFTR protein (termed
CFTR potentiators)40 to simulate such a proof-of-concept screen
(for detailed compound description, see online supplementary
table S1). Applying various drug combinations to our cultures, we
faithfully rescued the CF phenotype (ﬁgure 5F). Notably, CF-P1
organoids harbouring a premature stop codon in the CFTR gene
seemed to be less amenable for corrector compound-mediated
rescue (ﬁgure 5F, G; green and red boxes). Therefore, our newly
developed culture system is not only suitable to address develop-
mental questions but also represents a novel drug-screening plat-
form to develop and test future therapeutic options.
Modiﬁed mRNAs allow CFTR gene supplementation in POs
The most desirable treatment approach for an inherited disease
is curative gene therapy. However, current regimens for gene
repair such as DNA-based gene therapy are either hampered by
Figure 4 Differentiation of cystic ﬁbrosis (CF)-mutated human-induced pluripotent stem cells towards pancreatic progenitors. (A–C)
Immunostaining (left) and representative FACS plots (right) for the deﬁnitive endoderm (DE) markers SOX17, CXCR4 and c-KIT, PDX1 and PDX1/
NKX6.1-positive cells at day 4 (A), day 10 (B) and day 14 (C). Genotypes are indicated. Scale bars: 100 mm. (D–F) Quantiﬁcation of several FACS
experiments at (D) DE, (E) pancreatic endoderm and (F) pancreatic progenitor stage detected using indicated marker combinations. Data are shown
as mean±SEM from three independent experiments. Individual experiments were grouped according to genotype (wildtype vs CF) and statistically
compared via t-test.
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safety concerns41 and/or low gene transfer efﬁciency.42 The
application of nucleotide chemically modiﬁed mRNA (cmRNA),
circumvents these caveats and further ensures high stability, thus
representing a promising therapeutic tool. Previous work by our
group and others has shown that delivery of cmRNA leads to
therapeutic levels of protein expression as a result of high gene
transfer efﬁciency, higher stability and/or low immunogenicity,
and hence, can even be used for life-saving genome editing in
vivo.18 Unfortunately, labour and cost-intensive testing is
required to identify organ-optimised and personalised cmRNAs
for gene supplementation in vivo. Organoids, however, would
be a desirable system to screen and validate cmRNAs in vitro
for subsequent in vivo applications, although the utility of such
a system remains to be validated. To address the latter, we aimed
to establish cmRNAs optimised for POs in an attempt to rescue
CFTR function in CF POs. We tested a set of different modiﬁca-
tions (unpublished data) using mRNAs encoding for dsRed.
With one modiﬁcation, we obtained robust dsRed protein
expression even 7 days after transfection in subsequently devel-
oped organoids independent of the culture regimen (ﬁgure 6A).
Figure 5 Generation of pancreatic organoids (POs) from cystic ﬁbrosis (CF)-mutated patients and phenotypic rescue. (A) Time course of growing
POs derived from control (Con) and CF- human-induced pluripotent stem cells (iPSCs) (CF-P1). (B) Images of POs before and after 2 hours treatment
with forskolin and IBMX. (C) Corresponding quantiﬁcation from forskolin-induced PO swelling (B) in each indicated genotype. Error bars represent
mean area increase±SEM of three individual wells, statistical signiﬁcance was determined by two-tailed t-test, *p<0.05. (D) Luminal
(N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide) (MQAE) ﬂuorescence (Cl−-sensitive dye) is quenched in wild-type (WT) organoids
indicating an increase in intraluminal chloride secretion after cystic ﬁbrosis transmembrane conductance regulator (CFTR) activation and subsequent
challenge with a chloride ion-rich solution, which is impaired in CF organoids. (E) Gene set enrichment analysis of three gene signatures were
performed on WT ESC/iPSC (CON) and CF samples. Genes involved in cell proliferation, immune response and oestrogen receptor 1 (ESR1) signalling
are negatively correlated in CFTR-mutated pancreatic organoids as previously described for airway cells.54 CON: HUES8 (WT ESC line, n=2) and Con1
(WT iPSC) line, n=2), CF: CF-P1 and CF-P2, n=2 each. ES, enrichment score; FDR, false discovery rate; FWER, family-wise error rate; NES, normalised
enrichment score. (F and G) Small-scale rescue screen using indicated compounds in two independent CF patient-derived iPSC-POs. Organoids were
preincubated with compounds before applying FSK/IBMX. Green (CF-P1) and red (CF-P2) boxes mark most pronounced rescue, which is represented
as quantiﬁcation of 8–12 organoids in (G). Dotted lines indicate relative organoid size upon treatment with DMSO as a solvent control. All scale
bars: 50 mm.
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This modiﬁcation was used for CFTR gene supplementation in
CF organoids and indeed upon activation of CFTR using for-
skolin and IBMX in the organoid-swelling assay described above
a signiﬁcant rescue could be observed in CFTR mutants (ﬁgure
6B, C).
POs resemble human fetal pancreas upon orthotopic
transplantation in mice
Finally, we aimed for a xenotransplantation approach in an
attempt to generate a humanised animal model for pancreatic
disease. Upon orthotopic PO transplantation into the murine
pancreas (schematic outline in ﬁgure 7A), large grafts of human
tissue readily visible with the naked eye could be observed.
Human origin of the grafts was visualised with human-speciﬁc
CK8 staining (ﬁgure 7B). Trilineage differentiation potential of
PP cells, which gave rise to POs, is shown by immunohistochem-
istry for AMY, CK19 and insulin (ﬁgure 7B). Overall, morph-
ology and graft size in H&E staining between WT and
CF-derived organoids did not differ (ﬁgure 7B). Consequently,
detailed immunophenotyping of the grafts was performed. In
line with morphological appearance, acinar-like cells stained
positive for several acinar marker genes such as AMY and
chymotrypsin C, while ductal structures expressed CK19
(ﬁgure 7C, D and online supplementary ﬁgure S10A). To assess
the maturity of the grafts, co-staining for acinar and ductal
lineage markers with various progenitor cell markers such as
SOX9,43 PDX144 and NKX6.111 was performed. Most acinar
and ductal cells still stained positive for SOX9,43 while only
acinar cells showed remaining PDX1 positivity.44 Vice versa, we
noted a mutual exclusive expression pattern for NKX6.1 and
acinar markers such as AMY, indicating that these cells lost their
acinar potency as described previously.11 This observation ﬁts
well with the data obtained in lineage tracing studies done in
mice11 43 44 and would indicate a developmental stage of a
human Carnegie Stage CS20 to CS23 (ﬁgure 7D and online
supplementary ﬁgure S10B). Staining for α-smooth muscle actin
(α-SMA) also revealed signs of neovascularisation in the grafts
(ﬁgure 7C). Similar to in vitro cultured organoids, apoptotic
cells were hardly detectable, while Ki67-positive cells could be
frequently found in both genotypes (ﬁgure 7B and online sup-
plementary ﬁgure S10C). As expected, CFTR staining was more
diffuse in CF grafts compared with the luminal, membranous
pattern in WT grafts (ﬁgure 7E, F). Overall, there were no
observable differences in the expression of the investigated
developmental markers between WT and CF-derived grafts at
least based on the performed semi-quantitative analyses in the
not fully maturated grafts. In summary, our novel PO platform
exceeds previous ﬁndings obtained in zebraﬁsh45 that the peri-
natal CF phenotype results from functional CFTR defects due
to defective ﬂuid secretion and not from defective pancreatic
development. Further maturation time of the grafts in vivo is
required to provide additional data.
DISCUSSION
Progress to generate acinar/ductal cells from multipotent PPs
remains slow in light of a recently published study investigating
cancer organoids derived from PSC.14 Our study represents pro-
gress to the ﬁeld in terms of providing a new disease-modelling
platform. We present a serum-free and a largely small-molecule-
based approach to derive pancreatic acinar-like and duct-like
cells using a cost-effective 3D organoid culture system. These
organoids faithfully represent human pancreas on a global gene
expression level and upon orthotopic transplantation into
immune-deﬁcient mice. The stepwise commitment process in
generating organoids complemented with subsequent matur-
ation in vivo can pinpoint developmental defects to a distinct
time frame and therefore may facilitate the study of pancreatic
diseases in humanised mice as shown here for CF. The impres-
sive success of graft implantation could be further improved by
repetitive transplantations at various sites of the pancreas,
although it remains unclear whether human pancreatic progeny
will also functionally integrate within the murine host. In that
sense, it is necessary to further deﬁne maturity and purity of
PO-derived grafts in the future. This is indispensable for the
modelling of a less-well-characterised disease.
PO cultures derived from primary cancer specimens have
been shown to be a superior model for pancreatic cancer.46
These organoids recapitulate the pancreatic niche extremely
Figure 5 Continued.
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well, but exhibit a limited take rate in culture after endoscopic
ﬁne-needle biopsies and are strongly dependent on a set of
highly expensive growth factors whose omission leads to culture
deterioration.46 47 Still, techniques to derive and culture orga-
noids obtained from human adult epithelium are far more
developed and better characterised than PSC-derived organoids
and have unclosed novel avenues for translational research as
shown recently in a rectal biopsy-derived organoid screen for
CF drugs.48 However, organoids generated from PSCs require
less growth factor supplementation most likely due to the fact
that the multipotent nature of PPs together with incomplete
purity allows for the generation of a self-organising niche pro-
ducing the required factors. Indeed, similar observations have
been made when intestinal organoids were derived from either
Figure 6 mRNA-mediated gene transfer in pancreatic organoids. (A) Representative image of pancreatic organoids (POs) in suspension culture
7 days after transfection with a speciﬁcally modiﬁed dsRed mRNA. Right, indicates subsequent development of a similarly transfected organoid in
matrigel culture over time. (B and C) Rescue of defective cystic ﬁbrosis transmembrane conductance regulator (CFTR) function in CF-human-induced
pluripotent stem cell (iPSC)-derived pancreatic organoids as assessed by the forskolin-induced swelling assay 4 days after transfection with a CFTR
mRNA with similar modiﬁcations as tested in (A). (B) Images of POs before and after 2 hours treatment with forskolin and IBMX and (C)
corresponding quantiﬁcation in indicated genotypes. Values represent mean±SEM of 12 organoids out of 3 independent wells analysed per
condition. Asterisks denote signiﬁcant difference between FSK/IBMX and DMSO treatment. Hash indicates effect of CFTR compared with
dsRed-mRNA treatment. Statistical signiﬁcance was determined by two-tailed t-test, */#p<0.05, **p<0.01. Scale bars 50 mm.
Hohwieler M, et al. Gut 2016;0:1–14. doi:10.1136/gutjnl-2016-312423 11
Pancreas
group.bmj.com on February 6, 2017 - Published by http://gut.bmj.com/Downloaded from 
Figure 7 Orthotopic organoid transplantation in mice. (A) Schematic presentation of experimental set-up and pictures of pancreas tissue explanted
5 weeks after injection of pancreatic organoids (POs) into the pancreas of mice (left: overview, right: zoom-in). Dotted line represents putative graft.
(B) Immunohistochemical analysis of orthotopic pancreas grafts. Indicated markers show trilineage potential and proliferative capacity of the
transplanted POs (amylase-acinar, cytokeratin 19 (CK19)-ductal, insulin-endocrine, Ki67-proliferation). Genotype and markers as indicated.
Human-speciﬁc cytokeratin 8 (CK8) conﬁrms human origin. Red arrowheads mark few endocrine cells being insulin positive. H&E, scale bars
400 mm, immunohistochemical images (human CK8, amylase, CK19, insulin, Ki67, scale bars 100 mm). (C–F) Immunoﬂuorescence analysis of
orthotopic pancreas grafts. Genotype and markers as indicated. (C) Human-speciﬁc cytokeratin 8 (CK8) conﬁrms human origin. α-smooth muscle
actin (α-SMA) marks myoﬁbroblasts indicating putative vessel formation around exocrine structures. SOX9/CK19 co-labelling marks ductal structures
(D) PDX1 signal in CPA1-positive acinar structures indicates remaining progenitor marker activity in this lineage as known in mice.44 The majority of
present NKX6.1-positive cells (arrowheads) stain negative for amylase (AMY), indicating that the acinar lineage has lost this marker as expected
from developmental studies in mice.11 (E and F) Apical cystic ﬁbrosis transmembrane conductance regulator (CFTR) expression (arrowhead) in ductal
structures derived from grafted (E) wild-type organoids is lost in (F) cystic ﬁbrosis (CF) (asterisk marks the lumen). Dashed lines indicate graft/host
tissue border. Transplantation experiments were performed with pancreatic organoids (d21) generated from HUES8 (wild-type) or CF-P1 iPS cells (CF)
in FN-based suspension culture. Scale bars: 40 mm.
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PSCs or tissue biopsies.49 50 Heterogeneous pancreatic commit-
ment of individual organoids also provides room for further
improvement. While we noted virtually pure POs, structures
containing non-pancreatic progeny were also observed in our
cultures. During further culture, obvious signs of extra-
pancreatic lineage differentiation such as outgrowing neurons
(data not shown) became apparent. This is most likely due to
incomplete purity at the PP stage underlining the necessity to
further tailor this crucial step.
To provide proof of concept of the utility of this model for
studying pancreatic diseases, we decided to study pancreatic
facets of CF in a physiologically relevant environment. In vivo,
CFTR expression can be detected early on in the human blasto-
cyst stage51 while CF phenotypes become evident perinatally.
Current animal models lack the possibility to investigate whether
mutated CFTR may affect stepwise commitment to a mature pan-
creatic gland. Here, we challenge this hypothesis as pancreatic
development in CF seems to occur uninterrupted in vitro and in
vivo at least when there is no functional activity of the pancreas
triggered by nutrients. This observation is supported by a recent
study in zebraﬁsh.45 Of note, our marker-based characterisation
allots a Carnegie Stage 20-23 to our grafts, a differentiation stage
still far away from fully matured pancreas.
Various CFTR correctors and activators are about to enter the
clinic (https://clinicaltrials.gov/ct2/); however, randomised con-
trolled clinical trials are hindered by the imbalance between the
high number of compounds and genetically matched patients,
creating a demand for a personalised ex vivo drug testing system.
To our knowledge, all current drugs have been primarily designed
to rescue the lung phenotype of CF while pancreatic phenotypes
of CF have not been explored due to the lack of access to bona
ﬁde pancreatic cells and premature patient death caused by the
lung disease. Our reprogramming system using plucked human
hair as a cell source allows the fast and efﬁcient generation of
CF-patient-speciﬁc iPSCs.38 39 52 In turn, subsequent differenti-
ation towards POs would eventually allow preclinical and indivi-
dualised drug testing to evaluate whether a patient qualiﬁes for a
particular therapy or not. Proof of concept has been recently
given.48 Focusing on a curative approach, gene therapy is a rele-
vant topic in CF and other inherited pancreatic diseases, but this
approach is limited by possible off-target effects and a residual
integration risk. The application of nucleotide cmRNA, however,
circumvents these threats and further ensures high stability, thus
representing a promising therapeutic tool. Previous work by our
group and others has shown that delivery of cmRNA leads to
therapeutic levels of protein expression as a result of high gene
transfer efﬁciency, higher stability and/or low immunogenicity, and
hence, can even be used for life-saving genome editing in vivo.
Here, we complement POs with cmRNA-based CFTR gene sup-
plementation as an ex vivo test tool for various mRNA modiﬁca-
tions in an organ-speciﬁc context.
In summary, we provide a patient-speciﬁc platform to study
pancreatic development in a human context. Moreover, it pro-
vides the ability to mimic, investigate and rescue pancreatic phe-
notypes of inherited pancreatic disease in a dish but also in a
xenotransplantation assay generating human pancreas in mice.
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